Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models

Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic <i>C9ORF72</i> and <i>SOD1</i> mutation carriers exhibited increased wakefulness and reduced non-rapid eye movement sleep. Increased wakefulness correlated with diminished cognitive performance in both clinical cohorts. Similar changes in sleep macroarchitecture were observed in three ALS mouse models (<i>Sod1<sup>G86R</sup></i>, <i>Fus</i><sup>Δ<i>NLS/+</i></sup>, and <i>TDP43<sup>Q331K</sup></i>). A single oral administration of a dual-orexin receptor antagonist or intracerebroventricular delivery of melanin-concentrating hormone (MCH) through an osmotic pump over 15 days partially normalized sleep patterns in mouse models. MCH treatment did not extend the survival of <i>Sod1<sup>G86R</sup></i> mice but did decrease the loss of lumbar motor neurons. These findings suggest MCH and orexin signaling as potential targets to treat sleep alterations that arise in early stages of the disease.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2025-01-29
DOI
https://doi.org/10.1126/scitranslmed.adm7580
Citations
21
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
29.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models

Albert C. Ludolph, Patrick Weydt, Christina Lang, Matei Bolborea et al.
21 citations
Science Translational Medicine
Amyotrophic Lateral Sclerosis Research
29.17
article

Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models

Albert C. Ludolph, Patrick Weydt, Christina Lang, Matei Bolborea, Luc Dupuis, Pierre‐Hervé Luppi, Caroline Rouaux, Sébastien Arthaud, David Beckett, Francesco Roselli, Stéphane Dieterle, Laura Wassermann, Simon J. Guillot, Sandrine Da Cruz, Katharina Kandler, Johannes Dorst, Antje Knehr, Dorothée Lulé, Jan Kassubek, Marie Simonot, Pauline Vercruysse, Geoffrey Stuart‐Lopez, Luisa T. Balz
article en
21 citations

Abstract

Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic <i>C9ORF72</i> and <i>SOD1</i> mutation carriers exhibited increased wakefulness and reduced non-rapid eye movement sleep. Increased wakefulness correlated with diminished cognitive performance in both clinical cohorts. Similar changes in sleep macroarchitecture were observed in three ALS mouse models (<i>Sod1<sup>G86R</sup></i>, <i>Fus</i><sup>Δ<i>NLS/+</i></sup>, and <i>TDP43<sup>Q331K</sup></i>). A single oral administration of a dual-orexin receptor antagonist or intracerebroventricular delivery of melanin-concentrating hormone (MCH) through an osmotic pump over 15 days partially normalized sleep patterns in mouse models. MCH treatment did not extend the survival of <i>Sod1<sup>G86R</sup></i> mice but did decrease the loss of lumbar motor neurons. These findings suggest MCH and orexin signaling as potential targets to treat sleep alterations that arise in early stages of the disease.

Science Translational MedicineVol. 17(783)
Centre National de la Recherche Scientifique (FR), Inserm (FR), German Center for Neurodegenerative Diseases (DE), Centre de Recherche en Neurosciences de Lyon (FR), VIB-KU Leuven Center for Brain & Disease Research (BE), University Hospital Ulm (DE), Université de Strasbourg (FR)
Good health and well-being
Openalex Percentile: Top 0%
Amyotrophic Lateral Sclerosis Research
29.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.